Literature DB >> 17116331

Expression of complement regulators and receptors on human NT2-N neurons--effect of hypoxia and reoxygenation.

Elena D Pedersen1, Elisabeth Frøyland, Anne-Katrine Kvissel, Anne M Pharo, Bjørn S Skålhegg, Terje Rootwelt, Tom E Mollnes.   

Abstract

Complement activation can cause tissue damage in cerebral stroke by the release of biologically potent activation products and impaired function of regulatory proteins. We investigated the constitutive and hypoxia-reoxygenation-dependent expression of complement receptor 1 (CD35), membrane cofactor protein (CD46), decay-accelerating factor (CD55), protectin (CD59), and complement C3a and C5a receptors (C3aR and C5aR) on human NT2-N neurons. The effect of hypoxia-reoxygenation on C3d-deposition on neurons and endothelial cells was also investigated. NT2-N neurons were examined by cellular enzyme-linked immunosorbent assay and immunofluorescence microscopy. Endothelial cells were examined by flow cytometry. Three hours 1% or 0.1% hypoxia and 21h reoxygenation with 50% AB-serum were used to investigate the effect of hypoxia-reoxygenation on regulators and C3d-deposition. NT2-N neurons expressed significant amounts of CD59 (Clone H19/Clone BRIC229: p=0.000006/p=0.000003), CD46 (p=0.00006), CD55 (p=0.003) and C3aR (p=0.00003). CD35 and C5aR were not significantly expressed. There were no effects of hypoxia-reoxygenation on any of the regulators or receptors after 1% hypoxia and reoxygenation. However, CD55 (p=0.02) was down-regulated after 0.1% hypoxia and subsequent reoxygenation with AB-serum. There were no difference observed in the C3d-deposition during hypoxia-reoxygenation in either neurons or endothelial cells. In conclusion, human NT2-N neurons constitutively express C3aR, CD46, CD55 and, in particular, CD59. The cells may respond to locally produced C3a and, at the same time, be well protected against complement attack. Although severe hypoxia-reoxygenation may down-regulate CD55 expression, it does not seem to influence C3d-deposition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116331     DOI: 10.1016/j.molimm.2006.10.022

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  17 in total

Review 1.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 2.  Injury site-specific targeting of complement inhibitors for treating stroke.

Authors:  Ali Alawieh; Stephen Tomlinson
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

3.  Astrocyte Responses to Complement Peptide C3a are Highly Context-Dependent.

Authors:  Marcela Pekna; Sumen Siqin; Yolanda de Pablo; Anna Stokowska; Åsa Torinsson Naluai; Milos Pekny
Journal:  Neurochem Res       Date:  2022-09-12       Impact factor: 4.414

4.  Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice.

Authors:  Denise Harhausen; Uldus Khojasteh; Philip F Stahel; B Paul Morgan; Wilfried Nietfeld; Ulrich Dirnagl; George Trendelenburg
Journal:  J Neuroinflammation       Date:  2010-03-04       Impact factor: 8.322

5.  Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury.

Authors:  Ying Wang; Yansong Li; Shawn L Dalle Lucca; Milomir Simovic; George C Tsokos; Jurandir J Dalle Lucca
Journal:  J Neuroinflammation       Date:  2010-04-09       Impact factor: 8.322

6.  The alternative complement pathway regulates pathological angiogenesis in the retina.

Authors:  J Harry Sweigard; Ryoji Yanai; Philipp Gaissert; Magali Saint-Geniez; Keiko Kataoka; Aristomenis Thanos; Gregory L Stahl; John D Lambris; Kip M Connor
Journal:  FASEB J       Date:  2014-03-25       Impact factor: 5.191

7.  Low ficolin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke.

Authors:  George Füst; Lea Munthe-Fog; Zsolt Illes; Gábor Széplaki; Tihamér Molnar; Gabriella Pusch; Kristóf Hirschberg; Robert Szegedi; Zoltán Széplaki; Zoltán Prohászka; Mikkel-Ole Skjoedt; Peter Garred
Journal:  J Neuroinflammation       Date:  2011-12-29       Impact factor: 8.322

8.  Implication of complement system and its regulators in Alzheimer's disease.

Authors:  Martin V Kolev; Marieta M Ruseva; Claire L Harris; B Paul Morgan; Rossen M Donev
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

9.  Discovery of blood transcriptomic markers for depression in animal models and pilot validation in subjects with early-onset major depression.

Authors:  K Pajer; B M Andrus; W Gardner; A Lourie; B Strange; J Campo; J Bridge; K Blizinsky; K Dennis; P Vedell; G A Churchill; E E Redei
Journal:  Transl Psychiatry       Date:  2012-04-17       Impact factor: 6.222

Review 10.  Complement in the Homeostatic and Ischemic Brain.

Authors:  Ali Alawieh; Andrew Elvington; Stephen Tomlinson
Journal:  Front Immunol       Date:  2015-08-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.